Morgan Stanley 4 D Molecular Therapeutics, Inc. Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,460,234 shares of FDMT stock, worth $15.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,460,234
Previous 1,549,726
5.77%
Holding current value
$15.8 Million
Previous $49.4 Million
37.92%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding FDMT
# of Institutions
150Shares Held
56.3MCall Options Held
55.6KPut Options Held
167K-
Ra Capital Management, L.P. Boston, MA5.1MShares$55.2 Million1.61% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$53 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$47.7 Million10.13% of portfolio
-
Goldman Sachs Group Inc New York, NY4.13MShares$44.8 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.06MShares$44 Million2.8% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $351M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...